Mantra Bio, a San Francisco, CA-based developer of focused therapeutics primarily based on its engineering platform, raised $9M in Series A-2M funding.
New investor, Samsung Securities, joined present traders, together with 8VC, Viking Global Investors, Illumina, BoxGroup and Allen & Company in the spherical.
The firm intends to make use of the funds to advance the event of its lead focused exosome therapeutics program.
Led by Alex Mok, CEO, Mantra Bio is growing focused therapeutics primarily based on its proprietary exosome engineering platform, REVEAL. The platform, which integrates computational biology and bench lab automation, leverages the range of exosomes to allow the rational design of therapeutics directed at a variety of tissue and mobile targets. The firm’s applications embody focused exosome therapeutics for the therapy of sure ocular ailments and a novel vaccine for infectious illness. The lead program, in ophthalmology, employs engineered bi-specific exosomes that exactly goal a number of illness pathways.
Mantra’s total Series A funding, together with a $25M Series A-1, totals $34M.